SecBot SecBot
Biotech Drug Report Generated Jul 1, 2026

Opdivo

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since December 2014; continuous label expansions ongoing
Why 4/10
Opdivo is already approved and generating ~$10B in annual revenue; the most recent binary catalyst (cHL label expansion PDUFA) was approved on March 20, 2026, with no new hard-dated PDUFA or pivotal readout for Opdivo in the next ~12 months. As an approved, commercially mature product in a large-cap diversified pharma, impactScore is 4, label-expansion events and quarterly sales beats are incremental, not binary.
Actionable Insight NEUTRAL

Opdivo is a cash-cow mega-blockbuster with steady ~$10B/year revenue, but BMY stock is driven more by the broader pipeline (iberdomide PDUFA Aug 17, 2026), the patent cliff on Eliquis and Opdivo, and the growth of newer products (Camzyos, Breyanzi, Cobenfy). Investors should watch Opdivo's quarterly sales trajectory for erosion signs as biosimilar competition approaches (US patent cliff ~2028) and track BMY's ability to offset with the subcutaneous Opdivo Qvantig launch and new indications.

Price Chart

Loading chart...

Executive Summary

Opdivo (nivolumab) is Bristol-Myers Squibb's blockbuster PD-1 inhibitor immunotherapy, approved since 2014 across ~12 different cancer types including melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, and liver cancer. It generated $9.30 billion in 2024 sales (+3% YoY) and ~$10.0 billion in 2025, making it BMY's second-largest drug behind Eliquis. Opdivo competes head-to-head with Merck's Keytruda (which dominates the PD-1 market with >50% share). The drug faces a looming patent cliff, EU patent expiry around 2026 and US expiry around 2028, with biosimilar development underway by Amgen, Sandoz, and others. BMY is attempting to extend Opdivo's franchise with a subcutaneous formulation (Opdivo Qvantig) and new combination approvals. For BMY investors, Opdivo is a mature cash cow whose slow erosion will need to be backfilled by BMY's Growth Portfolio (Camzyos, Breyanzi, Cobenfy, iberdomide).

How It Works

Opdivo is an immunotherapy (a PD-1 immune checkpoint inhibitor). It works by blocking a protein called PD-1 on the surface of immune T-cells. This "releases the brakes" on the immune system, allowing the body's own T-cells to recognize and attack cancer cells more effectively.

Trial Status

Opdivo is FDA-approved across ~12 cancer indications. Latest approval was March 20, 2026 (nivolumab + AVD chemotherapy for previously untreated Stage III/IV classical Hodgkin lymphoma). A subcutaneous formulation (Opdivo Qvantig) was approved December 27, 2024. Additional Phase 2/3 combination studies continue across multiple tumor types.

The Two-Sided Case

▲ Bull Case5
Opdivo generated ~$10.0B in worldwide revenue in 2025, demonstrating durable commercial scale across a dozen approved indications (source: BMS Key Facts page - bms.com).
The subcutaneous formulation Opdivo Qvantig (approved Dec 2024) offers a convenience advantage over IV infusion and could extend the franchise lifecycle by winning market share from IV competitors and improving patient access (source: FDA.gov - fda.gov).
New label expansions are still being approved, March 2026 cHL approval (+AVD chemo), April 2025 HCC approval (+Yervoy), and June 2026 EU label expansion, showing ongoing regulatory momentum (source: FDA.gov - fda.gov).
BMY analyst consensus shows 14 buy/strongBuy ratings vs 20 hold and 2 sell, with a mean price target of $63.08, implying ~12.5% upside from $57.62.
Large institutional holders Vanguard ($11.7B), BlackRock ($10.4B), and State Street ($6.0B) maintain significant BMY positions.
▼ Bear Case5
Keytruda (Merck) dominates the PD-1 inhibitor market with >50% share, consistently outpacing Opdivo in new approvals and indications (source: DelveInsight - delveinsight.com).
Opdivo patents expire in the EU around 2026 and the US around 2028, opening the door to biosimilar competition. Amgen has already filed IPR challenges to BMS patents, and Indian biosimilar entrants like Zydus are preparing to launch (source: DrugPatentWatch - drugpatentwatch.com; Cancerworld - cancerworld.net).
The PD-1/PD-L1 inhibitor market is crowded with competitors including Roche's Tecentriq, AstraZeneca's Imfinzi, and Sanofi's Libtayo, all competing for the same indications (source: Synapse PatSnap - synapse.patsnap.com).
BMY's quant composite score is -22 (weak) with factor alignment of only 1, and earnings estimate revisions have been deteriorating (30-day revision direction: deteriorating).
2027 revenue is projected to decline ~2.3% to $46.2B, reflecting the expected impact of patent expirations across BMY's portfolio including Opdivo and Eliquis.

Upcoming Catalysts

  • Quarterly sales reports tracking Opdivo revenue trajectory vs consensus expectations
  • Ongoing label expansion decisions from FDA and EMA for combination regimens
  • Biosimilar competitive developments (Amgen IPR decisions, Sandoz JPB898 trial results, Zydus market entry)
  • SubQ formulation (Opdivo Qvantig) commercial adoption and payer coverage decisions
  • BMY earnings reports (next expected mid-2026) with Growth Portfolio vs Legacy Portfolio mix update

Source Filing

The SEC filing that triggered this drug report:

BRISTOL MYERS SQUIBB CO SEC filing BMY ·Accession 0000014272-26-000002

Sources · 15

Hover a chip for the title
1 bms.com2 fda.gov3 fda.gov4 drugs.com5 drugpatentwatch.com6 cancerworld.net7 precisionmedicineonline.com8 delveinsight.com9 synapse.patsnap.com10 legalnewsfeed.com11 pearceip.law12 fda.gov13 sec.gov14 en.wikipedia.org15 clival.com